Skip to Content

Enfortumab Vedotin as Neoadjuvant Treatment for MIBC

Patients with muscle-invasive bladder cancer (MIBC), who are cisplatin-ineligible, show promising antitumor activity with enfortumab vedotin monotherapy as neoadjuvant treatment. That is the conclusion from a newly published study presented by MD and Professor Daniel Petrylak in this MEDtalk.

Daniel Petrylak

Få tilgang

Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.

Back to top